NetworkNewsBreaks

TuesdayJun 07, 2022 12:52 pm

NetworkNewsBreaks – Why Odyssey Health Inc. (ODYY) Is ‘One to Watch’

Odyssey Health (OTC: ODYY) is a medical technology company focused on developing lifesaving products that offer technological and clinical advantages over current standards of care. Guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems, and forging strategic partnerships, the company boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices. “Odyssey has two pharmaceutical products in development: PRV-002 and PRV-001. PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory…

Continue Reading

TuesdayJun 07, 2022 11:26 am

NetworkNewsBreaks – Coinbase Global Inc. (NASDAQ: COIN) Announces Participation in Upcoming Morgan Stanley US Financials, Payments & CRE Conference

Coinbase Global Inc. (NASDAQ: COIN) will be presenting at the next Morgan Stanley US Financials, Payments & CRE Conference. The company announced that Brett Tejpaul, head of Coinbase Institutional, will be part of  a fireside chat at the Morgan Stanley conference. The presentation is slated for Monday, June 13, 2022, with the fireside chat scheduled to start at 3:15 p.m. ET. Those interested can watch the live presentation on the Coinbase investor relations website; a replay of the presentation will also be available. Started in 2012, Coinbase was established with the goal of building a more fair, accessible, efficient and…

Continue Reading

TuesdayJun 07, 2022 11:16 am

NetworkNewsBreaks – SPYR Technologies (SPYR) Announces FCC Approval, PTCRB Certification of GeoTraq’s Tracker Module

SPYR (OTCQB: SPYR), a technology company, today announced that its subsidiary GeoTraq’s Tracker Module (“GT-TM100”) is FCC approved and ready for the market. According to the update, the GT-TM100 has successfully completed certification testing required by the PCS Type Certification Review Board (“PTCRB”) and is in compliance with FCC Part 15 Subpart B, Class B (“sDoC”) performance specifications. The PTCRB program provides confidence that devices perform optimally on mobile wireless networks and conform with global standards. “The Tracker Module is a complete, ‘self-contained’ device that can easily be inserted into any device, asset or package to connect it to the…

Continue Reading

TuesdayJun 07, 2022 11:06 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Acquisition of Entheon Biomedical’s DMT Clinical Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cybin, is expected to accelerate Cybin’s CYB004 program timeline by an estimated nine months; CYB004 is Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders.. The phase 1 N,N-dimethyltryptamine (“DMT”) study is focused on evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and is expected to significantly impact the clinical path forward. Renamed CYB004-E, the phase 1 EBRX-101…

Continue Reading

TuesdayJun 07, 2022 10:12 am

NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as…

Continue Reading

MondayJun 06, 2022 3:34 pm

NetworkNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Earns “In-Process” Rating from US Government FedRAMP Program

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies committed to enhancing U.S. security operations, announced that as part of its efforts to pursue Authority to Authorize (“ATO”) in the Federal Risk and Authorization Management Program (“FedRAMP”), the company achieved “In-Process” status. A government-wide program that promotes the adoption of secure cloud services across the federal government, FedRAMP provides a standardized approach to security assessment and authorization, and provides continuous monitoring for cloud products and services. Knightscope has been working to design a secure, hardened environment specifically to support government clients; as part of those efforts, the company built…

Continue Reading

MondayJun 06, 2022 3:15 pm

NetworkNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Platform ‘Is the Right Technology at the Right Time’

Aditxt (NASDAQ: ADTX) recently entered into a multi-year partnership with Guthy-Renker LLC- affiliated GRS. The partnership focuses on building awareness and visibility among consumers and health care providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. “AditxtScore is the right technology at the right time. Our first application, AditxtScore for COVID-19, delivers timely reports on vulnerability and immune status to SARS-CoV-2 and its known variants, giving consumers and their physicians the data they need to make informed health decisions for themselves and their families,” Aditxt CEO and Co-Founder Amro Albanna was quoted in a recent article. Albanna added that the company’s…

Continue Reading

MondayJun 06, 2022 2:21 pm

NetworkNewsBreaks – HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) Issues May 2022 Production Update

HIVE Blockchain Technologies (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) today announced production figures from its global Bitcoin and Ethereum mining operations for the month of May 2022. Among the highlights, the company reported a BTC HODL balance of 3,186 Bitcoin as of June 5, 2022. “We are pleased to report in May HIVE continued its strong momentum in expanding our hashrate, notably our Bitcoin mining hashrate grew by 8% this month, through installations and electrical upgrades,” said Frank Holmes, executive chairman of HIVE. “In May we produced an average of 8.8 BTC per day, and we are pleased to note…

Continue Reading

MondayJun 06, 2022 2:14 pm

NetworkNewsBreaks – Advanced Container Technologies Inc. (ACTX), Growpods Spotlighted in Borgen Magazine Article

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of self-contained, automated, indoor “micro-farms” called GrowPods, along with related equipment and supplies, were featured in an article published in Borgen magazine. The article, titled “How GrowPods Are Aiding Global Food Security,” notes that ACTX’s GrowPods “have the potential to help achieve global food security.” Noting that the consequences of global food insecurity are enormous, the article reports that Advanced Container Technologies and the innovative GrowPods may help solve the issue of global food shortages. Because the modular hydroponic farms can be located anywhere and provide an easily, accessible way to grow…

Continue Reading

MondayJun 06, 2022 2:06 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Takes First Regulatory Step with FDA for Development of DehydraTECH-CBD in Treating Hypertension

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has successfully filed a pre-Investigational New Drug (“IND”) meeting request letter with the U.S. Food and Drug Administration (“FDA”). According to the update, the FDA has already responded to and confirmed Lexaria’s filing and has provided a target date of July 30, 2022, subject to certain conditions being met. “We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” said John Docherty, president of Lexaria. “Submission of this request letter…

Continue Reading